Tempus AI Jumps 54.8% as DCF Sees 33.1% Upside Despite $1.5 Billion Deal Risks
Updated
Updated · Yahoo Finance · Aug 22
Tempus AI Jumps 54.8% as DCF Sees 33.1% Upside Despite $1.5 Billion Deal Risks
1 articles · Updated · Yahoo Finance · Aug 22
Summary
Tempus AI has rallied 54.8% over the past month, intensifying debate over whether the stock still offers value after the sharp run-up.
A discounted cash flow model pegs intrinsic value at about $109 a share, implying the stock trades at a 33.1% discount despite the recent surge.
That upside case rests on stronger growth expectations tied to a positive cancer vaccine trial and Tempus AI's planned $1.5 billion acquisition of Personalis.
Broader valuation checks are less supportive: Tempus AI passes only 2 of 6 screens, while latest-12-month free cash flow showed roughly $274.1 million in outflows.
The key question is whether future cash-flow gains from the Personalis deal can outweigh integration and execution risks enough to justify further upside.